

09/738,540

page 7

In the claims

Please amend the claims as follows:

5. (Amended) The method of any one of claims 1-4, wherein the LFA-1 antagonist is an anti-LFA-1 antibody.
6. (Amended) The method of claim 17, wherein the anti-CD11a antibody is a non T-cell depleting antibody.
7. (Amended) The method of any one of claims 1-6 and 17, wherein the TNF- α antagonist is an immunoadhesin.

Please cancel claims 10-16 which are directed to a non-elected invention.

Please add claims 17, 18 and 19.

- 17. The method of claim 5, wherein the anti-LFA-1 antibody is an anti-CD11a antibody.--
18. The method of claim 10, wherein the fusion protein consists of the extracellular ligand binding portion of human tumor necrosis factor receptor linked to the hinge region, CH2 domain, and CH3 domain of human IgG1.
19. The method of claim 4, further comprising administering to the mammal an effective amount of methotrexate.--